V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20216165 | 20155803 | 1.76 | 66.4 | Palliative (P) | 2017-09-26 | 2017-10-27 | Sorafenib | 02 | N | SORAFENIB | 100963750 |
| 20216166 | 20155804 | 1.74 | 62.2 | null | 2019-10-31 | 2019-11-01 | EOX | 02 | null | EOX | 101046615 |
| 20216172 | 20155805 | 1.62 | 66.9 | Palliative (P) | 2017-06-23 | 2017-09-17 | EOX | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 101758348 |
| 20216173 | 20155806 | 1.72 | 86 | Palliative (P) | 2019-07-17 | 2019-07-17 | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 2 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101823820 |
| 20216175 | 20155807 | 1.64 | 70 | Disease modification (D) | 2017-12-22 | 2017-12-27 | Capecitabine 35days + RT | N | Y | EOX | 100199795 |
| 20216189 | 20155808 | 1.5 | 75.3 | Palliative (P) | 2019-06-01 | 2019-08-13 | Capecitabine 35days + RT | 02 | Y | CAPECITABINE + RT | 101276757 |
| 20216191 | 20155809 | 1.76 | 98.9 | Palliative (P) | 2018-05-12 | 2018-09-05 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 02 | null | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101295520 |
| 20216192 | 20155810 | null | null | null | 2019-12-16 | 2019-12-23 | Capecitabine 35days + RT | Y | null | EOX | 101499425 |
| 20216194 | 20155811 | 1.79 | 59 | Palliative (P) | 2018-12-07 | 2019-01-04 | Oxaliplatin + Raltitrexed | 02 | null | OXALIPLATIN + RALTITREXED | 100172662 |
| 20216195 | 20155812 | 1.69 | 64.4 | Palliative (P) | 2017-10-24 | 2017-12-31 | IRINOTECAN + MDG + PANITUMUMAB | 2 | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100190030 |
| 20216201 | 20155813 | 1.63 | 82.8 | null | 2020-02-20 | 2020-03-16 | Trial Unspecified | 02 | Y | TRIAL | 100154221 |
| 20216203 | 20155814 | 1.7 | 78 | Palliative (P) | 2019-08-16 | 2019-08-20 | Sorafenib | 02 | N | SORAFENIB | 101603403 |
| 20216207 | 20155815 | 1.43 | 102 | Palliative (P) | 2018-02-09 | 2018-02-16 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 101754083 |
| 20216208 | 20155816 | 1.78 | 70.5 | Palliative (P) | 2017-07-29 | 2017-07-29 | Cetuximab + Oxaliplatin + MdG Maint | 02 | Y | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101215533 |
| 20216210 | 20155817 | 1.69 | 107 | Neo-adjuvant (N) | 2021-01-26 | 2021-02-04 | EOX | 02 | Y | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101660393 |
| 20216213 | 20155818 | 1.81 | 74 | Palliative (P) | 2020-03-29 | 2020-03-29 | CAPECITABINE + RT | 02 | N | CAPECITABINE + RT | 101255452 |
| 20216216 | 20155819 | 1.57 | 64.8 | Neo-adjuvant (N) | 2018-04-30 | 2018-05-08 | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101577149 |
| 20216230 | 20155820 | 1.87 | 69.2 | Palliative (P) | 2017-10-07 | 2017-10-08 | Cetuximab + FOLFIRI cycle 2 onwards | 02 | N | SORAFENIB | 100567733 |
| 20216239 | 20155821 | 1.61 | 79.6 | null | 2020-06-12 | 2020-07-09 | EOX | 02 | N | EOX | 100410098 |
| 20216243 | 20155822 | 1.88 | 18.9 | null | 2016-11-19 | 2016-12-17 | Cetuximab + Oxaliplatin + MdG Maint | 02 | null | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101577944 |
| 20216244 | 20155823 | 1.72 | null | Palliative (P) | 2017-01-22 | 2017-02-26 | EOX | 02 | null | EOX | 101755791 |
| 20216246 | 20155824 | 1.72 | 78.7 | Adjuvant (A) | 2016-11-07 | 2017-02-28 | Trial Unspecified | 02 | Y | TRIAL | 101591343 |
| 20216249 | 20155826 | 1.59 | 74.3 | null | 2019-09-23 | 2020-01-01 | EOX | 02 | null | CETUXIMAB + IRINOTECAN + MDG | 101502443 |
| 20216251 | 20155827 | 1.69 | 65.4 | Adjuvant (A) | 2019-11-17 | 2019-12-12 | Oxaliplatin + Raltitrexed | 01 | N | OXALIPLATIN + RALTITREXED | 101145492 |
| 20216252 | 20155828 | 1.41 | 72.4 | Palliative (P) | 2019-01-10 | 2019-01-10 | EOX | 02 | N | EOX | 101051557 |
| 20216253 | 20155829 | 1.81 | 102.6 | Palliative (P) | 2020-01-14 | 2021-08-06 | Cetuximab + FLUOROURACIL + OXALIPLATIN | 02 | null | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100981389 |
| 20216254 | 20155830 | 1.84 | 76.3 | null | 2020-06-26 | 2020-07-08 | EOX | 2 | null | CETUXIMAB + IRINOTECAN + MDG | 101682879 |
| 20216256 | 20155831 | null | null | 03 | 2019-10-19 | 2019-11-19 | Trial Unspecified | 02 | N | TRIAL | 101864854 |
| 20216261 | 20155832 | 1.62 | 78.4 | Palliative (P) | 2016-08-25 | 2016-10-23 | Sorafenib | 2 | N | SORAFENIB | 101864460 |
| 20216262 | 20155833 | 1.83 | null | null | 2016-02-23 | 2016-02-23 | Cetuximab + Oxaliplatin + MdG Maint | 02 | null | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101038159 |
| 20216265 | 20155834 | 1.75 | 57.1 | Neo-adjuvant (N) | 2016-10-22 | 2016-10-26 | Trial Unspecified | 01 | Y | TRIAL | 101060287 |
| 20216267 | 20155835 | 1.64 | 70.6 | Palliative (P) | 2020-02-07 | 2020-02-07 | EOX | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 101024602 |
| 20216273 | 20155836 | 1.64 | 58.1 | Palliative (P) | 2017-10-12 | 2017-10-13 | CETUXIMAB + IRINOTECAN + MDG | N | N | CETUXIMAB + IRINOTECAN + MDG | 100554096 |
| 20216275 | 20155837 | 1.79 | 61.9 | Palliative (P) | 2016-09-28 | 2016-09-28 | EOX | 2 | N | TRIAL | 101865503 |
| 20216277 | 20155838 | null | 61 | Palliative (P) | 2016-05-10 | 2016-06-01 | CAPECITABINE + RT | 02 | N | CAPECITABINE + RT | 101139226 |
| 20216278 | 20155839 | 1.85 | 82.5 | Palliative (P) | 2019-10-08 | 2019-12-05 | Sorafenib | 02 | N | SORAFENIB | 100478108 |
| 20216281 | 20155840 | 1.57 | 93.3 | Neo-adjuvant (N) | 2021-02-13 | 2021-03-06 | EOX | 02 | null | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100245452 |
| 20216282 | 20155841 | 1.75 | 80.2 | Palliative (P) | 2017-05-10 | 2017-05-10 | EOX | 1 | N | EOX | 100603460 |
| 20216283 | 20155842 | 1.69 | null | Palliative (P) | 2017-10-09 | 2017-10-17 | EOX | 02 | N | CAPECITABINE + RT | 100093604 |
| 20216291 | 20155843 | 1.92 | 69.2 | Palliative (P) | 2019-06-08 | 2020-03-27 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 100003848 |
| 20216292 | 20155844 | null | 107.55 | null | 2019-04-22 | 2019-07-15 | Sorafenib | 02 | null | SORAFENIB | 101681367 |
| 20216297 | 20155845 | 0 | 59.1 | null | null | 2019-10-04 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 101358908 |
| 20216300 | 20155846 | 1.57 | null | null | 2021-04-25 | 2021-09-05 | EOX | 02 | null | EOX | 100250445 |
| 20216305 | 20155847 | 1.75 | 69.1 | Palliative (P) | 2019-06-16 | 2019-07-13 | CETUXIMAB + IRINOTECAN + MDG | 02 | null | CETUXIMAB + IRINOTECAN + MDG | 100185847 |
| 20216307 | 20155848 | 1.78 | 58.8 | null | 2018-05-13 | 2019-01-04 | Cetuximab + FOLFIRI cycle1 | N | N | CETUXIMAB + IRINOTECAN + MDG | 100405386 |
| 20216308 | 20155849 | 1.6 | 51.4 | null | 2019-08-01 | 2021-12-04 | Oxaliplatin + Raltitrexed | 02 | null | OXALIPLATIN + RALTITREXED | 101827284 |
| 20216310 | 20155850 | 0.76 | 72 | Palliative (P) | 2018-04-29 | 2018-05-14 | Cetuximab + FOLFIRI cycle 2 onwards | 1 | null | CETUXIMAB + IRINOTECAN + MDG | 100933913 |
| 20216313 | 20155851 | 1.76 | 107.5 | Disease modification (D) | 2021-05-27 | 2021-05-27 | Cetuximab + Oxaliplatin + MdG Maint | 01 | Y | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100925366 |
| 20216314 | 20155852 | 1.75 | 90.5 | Adjuvant (A) | null | 2017-10-24 | Sorafenib | Y | N | SORAFENIB | 100441786 |
| 20216318 | 20155853 | 1.85 | 108.8 | null | 2021-12-23 | 2022-01-12 | Panitumumab + Irinotecan + MdG | 02 | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101819198 |